Key facts
- This page summarizes Ross Haghighat's Form 4 filing for CHINOOK THERAPEUTICS, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 May 2023, 19:24.
Ross Haghighat - 26 May 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 26 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 May 2023, 19:24:29 UTC
- Prior SEC filing
- 04 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kirk Schumacher, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ross Haghighat filed Form 4 for CHINOOK THERAPEUTICS, INC. on 31 May 2023.
Change
- Previous filing in this sequence was filed on 04 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KDNY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,300
- Change %
- +2.7%
- Price
- Shares after
- 124,546
- Date
- 26 May 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KDNY
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,300
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 26 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,300
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Footnote F2
Each RSU represents a contingent right to receive one share of Issuer's common stock.
Footnote F3
100% of the RSUs vested on May 26, 2023, subject to the Reporting Persons continued service to the Issuer on the vesting date.